Fort Detrick, MD  –   Frederick, MD – On July 14, 2023, the Department of Defense (DOD) awarded $39.8 million to Kaléo, Inc. to develop the Reconstitution Autoinjector Device – Atropine (RAD-A).

The RAD-A is a novel wet/dry autoinjector device that will reconstitute dry atropine upon activation, critical in the treatment of nerve agent exposure. Successful completion of the development phase will allow Kaléo to achieve U.S. Food and Drug Administration approval and production capacity of RAD-A.

“The innovative approach led by a joint government and U.S.-based industry team enables the shelf-life of the autoinjector to be extended, and ultimately reduces the sustainment burden for the Joint Force,” said COL Matthew G. Clark, Joint Project Manager for the Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical). “Additionally, the RAD-A will serve as a platform technology for various medical countermeasures in defense of our warfighters.”

This effort was led by the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and the U.S. Army Contracting Command – Aberdeen Proving Ground, Edgewood Division.
 
About the JPEO-CBRND:
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) mission is to provide an integrated layered chemical, biological, radiological, and nuclear defense capabilities to the Joint Force across combined Joint All-Domain Operations. JPEO-CBRND’s goal is to enable the Joint Force to fight and win unencumbered by a CBRN environment. To learn more about JPEO-CBRND, visit: https://www.jpeocbrnd.osd.mil/, or follow JPEO-CBRND on social media @JPEOCBRND.